{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:00:25Z","timestamp":1785351625925,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cirrhosis is associated with a narrow balance between procoagulant and anticoagulant factors that may lead to potentially serious complications. Interpretation of laboratory tests, prevention of bleeding during invasive procedures, and use of anticoagulant drugs for the prevention and treatment of thromboembolism are often challenging. After reviewing the most contemporary literature, we hereby provide guidance to navigate the evidence and support clinical decisions. Based on current knowledge, prothrombin time and activated partial thromboplastin time do not accurately describe hemostasis in patients with cirrhosis and should not be used to predict bleeding. Rather, a careful assessment of patient and procedure-related variables better helps to identify patients at increased bleeding risk. Because procedure-related bleedings are uncommon in patients with cirrhosis, the use of prophylactic strategies is seldom necessary in daily practice. In case of perioperative bleeding, viscoelastometry may be useful to drive decisions on the use of transfusion products. Portal vein thrombosis is a common complication in patients with cirrhosis and requires a timely start of anticoagulant treatment, especially when vessel obstruction exceeds 50% of the lumen diameter. Treatment should be continued for at least 6 months. The direct oral anticoagulants are increasingly used in this setting, representing a valid alternative to the heparins and vitamin K antagonists. Atrial fibrillation in cirrhosis is associated with a high risk of ischemic stroke and treatment-related major bleeding. The benefit of anticoagulants is supported by the results of observational studies, and the direct oral anticoagulants are suggested as the first line of treatment also for this population. Clinical trial number: not applicable<\/jats:p>","DOI":"10.1007\/s11606-026-10478-4","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:14:06Z","timestamp":1778181246000},"page":"2937-2946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing Coagulation Abnormalities, Bleeding, and Thrombosis in Patients with Cirrhosis"],"prefix":"10.1007","volume":"41","author":[{"given":"Armando","family":"Tripodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"La Mura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Piscaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-8879","authenticated-orcid":false,"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"10478_CR1","doi-asserted-by":"crossref","unstructured":"Le P, Tatar M, Dasarathy S, Alkhouri N, Herman WH, Taksler GB, Deshpande A, Ye W, Adekunle OA, McCullough A, Rothberg MB. Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050. JAMA Netw Open. 2025;8(1):e2454707.","DOI":"10.1001\/jamanetworkopen.2024.54707"},{"key":"10478_CR2","doi-asserted-by":"crossref","unstructured":"North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988;319:983\u20139.","DOI":"10.1056\/NEJM198810133191505"},{"key":"10478_CR3","doi-asserted-by":"crossref","unstructured":"Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365:147-56.","DOI":"10.1056\/NEJMra1011170"},{"key":"10478_CR4","doi-asserted-by":"crossref","unstructured":"Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41:553-8.","DOI":"10.1002\/hep.20569"},{"key":"10478_CR5","doi-asserted-by":"crossref","unstructured":"Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006;44:440-5.","DOI":"10.1002\/hep.21266"},{"key":"10478_CR6","doi-asserted-by":"crossref","unstructured":"Lisman T, Bakhtiari K, Pereboom IT, Hendriks HG, Meijers JC, Porte RJ. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol. 2010;52:355-61.","DOI":"10.1016\/j.jhep.2009.12.001"},{"key":"10478_CR7","doi-asserted-by":"crossref","unstructured":"Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost. 2010;8:1994-2000.","DOI":"10.1111\/j.1538-7836.2010.03937.x"},{"key":"10478_CR8","doi-asserted-by":"crossref","unstructured":"Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using global coagulation\/anticoagulation testing. Br J Haematol. 2009;147:77-82.","DOI":"10.1111\/j.1365-2141.2009.07833.x"},{"key":"10478_CR9","doi-asserted-by":"crossref","unstructured":"Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53-61.","DOI":"10.1002\/hep.21231"},{"key":"10478_CR10","doi-asserted-by":"crossref","unstructured":"Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci. 1981;26:388-93.","DOI":"10.1007\/BF01313579"},{"key":"10478_CR11","doi-asserted-by":"crossref","unstructured":"Massicotte L, Beaulieu D, Thibeault L, Roy JD, Marleau D, Lapointe R, et al. Coagulation defects do not predict blood product requirements during liver transplantation. Transplantation. 2008;85:956-62.","DOI":"10.1097\/TP.0b013e318168fcd4"},{"key":"10478_CR12","doi-asserted-by":"crossref","unstructured":"Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonz\u00e1lez Abraldes J, et al.\u00a0European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123\u201330.","DOI":"10.1053\/j.gastro.2004.07.015"},{"key":"10478_CR13","doi-asserted-by":"crossref","unstructured":"Lodge JP, Jonas S, Oussoultzoglou E, Malag\u00f3 M, Jayr C, Cherqui D, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology. 2005;102:269-75.","DOI":"10.1097\/00000542-200502000-00006"},{"key":"10478_CR14","doi-asserted-by":"crossref","unstructured":"Zanetto A, Campello E, Bulato C, Willems R, Konings J, Roest M, et al. Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis. J Hepatol. 2025;82:1023-35.","DOI":"10.1016\/j.jhep.2024.12.008"},{"key":"10478_CR15","doi-asserted-by":"crossref","unstructured":"Lecchi A, La Marca S, Padovan L, Boscarino M, Peyvandi F, Tripodi A. Flow-chamber device (T-TAS) to diagnose patients suspected of platelet function defects. Blood Transfus. 2024;22:55-64.","DOI":"10.1016\/j.thromres.2024.03.017"},{"key":"10478_CR16","doi-asserted-by":"crossref","unstructured":"Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients with Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73:366-413.","DOI":"10.1002\/hep.31646"},{"key":"10478_CR17","doi-asserted-by":"crossref","unstructured":"Tripodi A, Primignani M, Chantarangkul V, Lemma L, Jovani M, Rebulla P, Mannucci PM. Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver Intern. 2013;33(3):362-67","DOI":"10.1111\/liv.12038"},{"key":"10478_CR18","doi-asserted-by":"crossref","unstructured":"Cattaneo M. Pseudothrombocytopenia and other conditions associated with spuriously low platelet counts. Haematologica. 2025;110:1677\u201392.","DOI":"10.3324\/haematol.2024.286234"},{"key":"10478_CR19","doi-asserted-by":"crossref","unstructured":"Erno JM, Villa E, Intagliata NM. Predicting and Preventing Bleeding in Patients With Cirrhosis Undergoing Procedures. Am J Gastroenterol. 2024;120:1163\u201370.","DOI":"10.14309\/ajg.0000000000003129"},{"key":"10478_CR20","doi-asserted-by":"crossref","unstructured":"Tosetti G, Farina E, Caccia R, Sorge A, Berzuini A, Valenti L, et al. Preprocedural prophylaxis with blood products in patients with cirrhosis: results from a survey of the Italian association for the study of the liver (AISF). Dig Liver Dis. 2022;54:1520\u20136.","DOI":"10.1016\/j.dld.2022.03.017"},{"key":"10478_CR21","doi-asserted-by":"crossref","unstructured":"La Mura V, Bitto N, Tripodi A. Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges. Expert Rev Hematol. 2022;15:1031\u201344.","DOI":"10.1080\/17474086.2022.2144217"},{"key":"10478_CR22","doi-asserted-by":"crossref","unstructured":"Maynard S, Marrinan E, Roberts L, Stanworth S. Does the Use of Viscoelastic Hemostatic Assays for Periprocedural Hemostasis Management in Liver Disease Improve Clinical Outcomes?. Transfus Med Rev. 2024;38(3):150823.","DOI":"10.1016\/j.tmrv.2024.150823"},{"key":"10478_CR23","doi-asserted-by":"crossref","unstructured":"Desborough MJ, Hockley B, Sekhar M, Burroughs AK, Stanworth SJ, Jairath V; National Audit Collaborative. Patterns of blood component use in cirrhosis: a nationwide study. Liver Int. 2016;36(4):522\u2013529","DOI":"10.1111\/liv.12999"},{"key":"10478_CR24","doi-asserted-by":"crossref","unstructured":"Giannini EG, Greco A, Marenco S, Adorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol. 2010;8:899\u2013902.","DOI":"10.1016\/j.cgh.2010.06.018"},{"key":"10478_CR25","doi-asserted-by":"crossref","unstructured":"Napolitano G, Iacobellis A, Merla A, Niro G, Valvano MR, Terracciano F, et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. Eur J Intern Med. 2017;38:79\u201382.","DOI":"10.1016\/j.ejim.2016.11.007"},{"key":"10478_CR26","doi-asserted-by":"crossref","unstructured":"Janko N, Majeed A, Commins I, Kemp W, Roberts SK. Procedural bleeding risk, rather than conventional coagulation tests, predicts procedure related bleeding in cirrhosis. Eur J Gastroenterol Hepatol. 2022;34:192\u20139.","DOI":"10.1097\/MEG.0000000000001948"},{"key":"10478_CR27","doi-asserted-by":"crossref","unstructured":"Alvaro D, Caporaso N, Giannini EG, Iacobellis A, Morelli M, Toniutto P, et al. Procedure related bleeding risk in patients with cirrhosis and severe thrombocytopenia. Eur J Clin Invest. 2021;51:e13508.","DOI":"10.1111\/eci.13508"},{"key":"10478_CR28","doi-asserted-by":"crossref","unstructured":"Intagliata NM, Rahimi RS, Higuera-de-la-Tijera F, Simonetto DA, Farias AQ, Mazo DF, et al. Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): an International, Prospective, Multicenter Observational Study. Gastroenterology. 2023;165:717-32.","DOI":"10.1053\/j.gastro.2023.05.046"},{"key":"10478_CR29","unstructured":"Riescher-Tuczkiewicz A, Caldwell SH, Kamath PS, Villa E, Rautou PE; Bleeding in liver diseases investigators. Expert opinion on bleeding risk from invasive procedures in cirrhosis. J Hepatol Rep. 2023;6:100986."},{"key":"10478_CR30","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol. 2022;76:1151\u201384.","DOI":"10.1016\/j.jhep.2021.09.003"},{"key":"10478_CR31","doi-asserted-by":"crossref","unstructured":"Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. Am J Gastroenterol. 2020;115:18\u201340.","DOI":"10.14309\/ajg.0000000000000486"},{"key":"10478_CR32","doi-asserted-by":"crossref","unstructured":"Roberts LN, Lisman T, Stanworth S, Hernandez-Gea V, Magnusson M, Tripodi A, et al. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: guidance from the SSC of the ISTH. J Thromb Haemost. 2022;20:39\u201347.","DOI":"10.1111\/jth.15562"},{"key":"10478_CR33","doi-asserted-by":"crossref","unstructured":"Depasse F, Binder NB, Mueller J, Wissel T, Schwers S, Germer M, et al. Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine. J Thromb Haemost. 2021;19:2907-17.","DOI":"10.1111\/jth.15529"},{"key":"10478_CR34","doi-asserted-by":"crossref","unstructured":"Gerotziafas GT, Depasse F, Busson J, Leflem L, Elalamy I, Samama MM. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram\u2010Thrombinoscope assay. Thromb J. 2005;3:16.","DOI":"10.1186\/1477-9560-3-16"},{"key":"10478_CR35","doi-asserted-by":"crossref","unstructured":"Lisman T. Procedural bleeding in patients with cirrhosis: From prediction towards prevention. J Hepatol. 2025;82:e330\u20131.","DOI":"10.1016\/j.jhep.2025.01.004"},{"key":"10478_CR36","doi-asserted-by":"crossref","unstructured":"Pan J, Wang L, Gao F, An Y, Yin Y, Guo X, et al. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. Eur J Intern Med. 2022;104:21\u201332.","DOI":"10.1016\/j.ejim.2022.05.032"},{"key":"10478_CR37","doi-asserted-by":"crossref","unstructured":"Senzolo M, Garcia-Tsao G, Garc\u00eda-Pag\u00e1n JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol. 2021;75:442\u201353.","DOI":"10.1016\/j.jhep.2021.04.029"},{"key":"10478_CR38","doi-asserted-by":"crossref","unstructured":"Sen S, Dahlberg KW. Physician\u2019s fear of anticoagulant therapy in nonvalvular atrial fibrillation. Am J Med Sci. 2014;348:513\u201321.","DOI":"10.1097\/MAJ.0000000000000349"},{"key":"10478_CR39","doi-asserted-by":"crossref","unstructured":"La Mura V, Braham S, Tosetti G, Branchi F, Bitto N, Moia M, et al. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2018;16:1146\u201352.e4.","DOI":"10.1016\/j.cgh.2017.10.016"},{"key":"10478_CR40","doi-asserted-by":"crossref","unstructured":"Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;153:480\u20137.e1.","DOI":"10.1053\/j.gastro.2017.04.042"},{"key":"10478_CR41","doi-asserted-by":"crossref","unstructured":"Pettinari I, Vukotic R, Stefanescu H, Pecorelli A, Morelli M, Grigoras C, et al. Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis. Am J Gastroenterol. 2019;114:258\u201366.","DOI":"10.1038\/s41395-018-0421-0"},{"key":"10478_CR42","doi-asserted-by":"crossref","unstructured":"Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients with Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatol Baltim Md. 2021;73:366\u2013413.","DOI":"10.1002\/hep.31646"},{"key":"10478_CR43","doi-asserted-by":"crossref","unstructured":"Guerrero A, Campo LD, Piscaglia F, Scheiner B, Han G, Violi F, et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis. J Hepatol. 2023;79:69\u201378.","DOI":"10.1016\/j.jhep.2023.02.023"},{"key":"10478_CR44","doi-asserted-by":"crossref","unstructured":"Davis JPE, Lim JK, Francis FF, Ahn J. AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients with Cirrhosis: expert Review. Gastroenterology. 2025;168:396-404.e1.","DOI":"10.1053\/j.gastro.2024.10.038"},{"key":"10478_CR45","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on vascular disease of the liver. J Hepatol. 2025:S0168\u20138278(25)02406\u20137. Online ahead of print."},{"key":"10478_CR46","doi-asserted-by":"crossref","unstructured":"Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou P-E, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatol Baltim Md. 2015;61:660\u20137.","DOI":"10.1002\/hep.27546"},{"key":"10478_CR47","doi-asserted-by":"crossref","unstructured":"Li Z, Xu W, Wang L, Chai L, Ageno W, Romeiro FG, et al. Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: a Systematic Review and Meta-analysis. Thromb Haemost. 2023;123:1072\u201388.","DOI":"10.1055\/s-0043-1770100"},{"key":"10478_CR48","doi-asserted-by":"crossref","unstructured":"van der Wall SJ, Klok FA, den Exter PL, Barrios D, Morillo R, Cannegieter SC, Jimenez D, Huisman MV. J Thromb Haemost. 2017;15(1):74\u20139.","DOI":"10.1111\/jth.13563"},{"key":"10478_CR49","doi-asserted-by":"crossref","unstructured":"Monaco G, Bucherini L, Stefanini B, Piscaglia F, Foschi FG, Ielasi L. Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: a state of art. World J Gastroenterol. 2023;29:4962\u201374.","DOI":"10.3748\/wjg.v29.i33.4962"},{"key":"10478_CR50","doi-asserted-by":"crossref","unstructured":"K\u00f6ckritz L, De Gottardi A, Trebicka J, Praktiknjo M. Portal vein thrombosis in patients with cirrhosis. Gastroenterol Rep. 2017;5:148\u201356.","DOI":"10.1093\/gastro\/gox014"},{"key":"10478_CR51","doi-asserted-by":"crossref","unstructured":"Benevento F, Pecorelli A, Stefanescu H, Sparchez Z, Vukotic R, Pettinari I, et al. Presence of hepatocellular carcinoma does not affect course and respose to anticoagulation of bland portal vein thrombosis in cirrhotic patients. J Hepatocell Carcinoma. 2023;10:473-82.","DOI":"10.2147\/JHC.S390777"},{"key":"10478_CR52","doi-asserted-by":"crossref","unstructured":"Darrat YH, Smer A, Elayi CS, Morales GX, Alqahtani F, Alkhouli M,\u00a0et al. Mortality and morbidity in patients with atrial fibrillation and liver cirrhosis. World J Cardiol. 2020;12:342-50.","DOI":"10.4330\/wjc.v12.i7.342"},{"key":"10478_CR53","doi-asserted-by":"crossref","unstructured":"Luo Y, Wu B, Wu Y, Peng L, Li Z, Zhu J, et al. Atrial fibrillation increases inpatient and 4-year all-cause mortality in critically ill patients with liver cirrhosis. Ann Transl Med. 2021;9:1239.","DOI":"10.21037\/atm-21-3111"},{"key":"10478_CR54","doi-asserted-by":"crossref","unstructured":"Huang WA, Dunipace EA, Sorg JM, Vaseghi M. Liver Disease as a Predictor of New-Onset Atrial Fibrillation. J Am Heart Assoc. 2018;7:e008703.","DOI":"10.1161\/JAHA.118.008703"},{"key":"10478_CR55","doi-asserted-by":"crossref","unstructured":"Karapedi E, Papadopoulos N, Trifylli EM, Koustas E, Deutsch M, Aloizos G. Anticoagulation in patients with atrial fibrillation and liver cirrhosis. Ann Gastroenterol. 2022;35(6):557-67.","DOI":"10.20524\/aog.2022.0745"},{"key":"10478_CR56","doi-asserted-by":"crossref","unstructured":"Gu W, Hortlik H, Erasmus HP, Shaaf L, Zeleke Y, Uschner FE, et al. Trends and the course of liver cirrhosis and its complications in Germany: nationwide population-based study (2005 to 2018). Lancet Reg Health Eur. 2021;12:100240.","DOI":"10.1016\/j.lanepe.2021.100240"},{"key":"10478_CR57","doi-asserted-by":"crossref","unstructured":"Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79:1212-9.","DOI":"10.1097\/HEP.0000000000000670"},{"key":"10478_CR58","doi-asserted-by":"crossref","unstructured":"Chokesuwattanaskul R, Thongprayoon C, Bathini T, O'Corragain OA, Sharma K, Preechawat S, et al. Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis. Eur J Gastroenterol Hepatol. 2019;31:514-9.","DOI":"10.1097\/MEG.0000000000001315"},{"key":"10478_CR59","doi-asserted-by":"crossref","unstructured":"B Riahi E, Adelborg K, Pedersen L, Kristensen SR, Hansen AT, S\u00f8rensen HT. Atrial fibrillation, liver cirrhosis, thrombosis, and bleeding: a Danish population-based cohort study. Res Pract Thromb Haemost. 2022;6:e12668.","DOI":"10.1002\/rth2.12668"},{"key":"10478_CR60","doi-asserted-by":"crossref","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3314-414.","DOI":"10.1093\/eurheartj\/ehae176"},{"key":"10478_CR61","doi-asserted-by":"crossref","unstructured":"Vandenberk B, Altieri MH, Liu H, Raj SR, Lee SS. Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension. Aliment Pharmacol Ther. 2023;57(3):290-303.","DOI":"10.1111\/apt.17368"},{"key":"10478_CR62","doi-asserted-by":"crossref","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-62.","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"10478_CR63","doi-asserted-by":"crossref","unstructured":"Simon TG, Schneeweiss S, Singer DE, Sreedhara SK, Lin KJ. Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2023;12:e026863.","DOI":"10.1161\/JAHA.122.026863"},{"key":"10478_CR64","doi-asserted-by":"crossref","unstructured":"Chokesuwattanaskul R, Thongprayoon C, Bathini T, Torres-Ortiz A, O'Corragain OA, Watthanasuntorn K, et al. Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: a systematic review and meta-analysis. Dig Liver Dis. 2019;51:489-95.","DOI":"10.1016\/j.dld.2018.12.001"},{"key":"10478_CR65","doi-asserted-by":"crossref","unstructured":"Hu T, Li YH, Han WQ, Maduray K, Chen TS, Hao L, et al. Direct Oral Anticoagulants versus Vitamin K Antagonists in Cirrhotic Patients with Atrial Fibrillation: update of Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2023;23:683-94.","DOI":"10.1007\/s40256-023-00598-1"},{"key":"10478_CR66","doi-asserted-by":"crossref","unstructured":"Cheng C, Hua J, Xiong L. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Cirrhotic Patients: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost. 2024;30:10760296241301402.","DOI":"10.1177\/10760296241301402"},{"key":"10478_CR67","doi-asserted-by":"crossref","unstructured":"Carlin S, Cuker A, Gatt A, Gendron N, Hernandez-Gea V, Meijer K, et al. Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH. J Thromb Haemost. 2024;22:2653-69.","DOI":"10.1016\/j.jtha.2024.05.023"},{"key":"10478_CR68","doi-asserted-by":"crossref","unstructured":"Kim D, Shim J, Choi EK, Oh IY, Kim J, Lee YS, Park J, Ko JS, Park KM, Sung JH, Park HW, Park HS, Kim JY, Kang KW, Kim D, Park JK, Kim DH, Kim JB, Yu HT, Kim TH, Uhm JS, Pak HN, Joung B; ALONE-AF Investigators. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025;334(14):1246\u201354.","DOI":"10.1001\/jama.2025.14679"},{"key":"10478_CR69","doi-asserted-by":"crossref","unstructured":"Verma A, Birnie DH, Jiang C, Heidb\u00fcchel H, Hindricks G, Kirchhof P, Healey JS, Wang Y, Dagres N, Deyell MW, Sanders P, Pathak RK, Koopman P, Nuyens D, Novak P, Amit G, Dussault C, Makanjee B, Quinn FR, Jolly U, Iden L, Kuniss M, Sharma M, Ha A, Essebag V, Champagne J, Hill MD, Smith EE, Wells GA; OCEAN Investigators. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. N Engl J Med. 2026;394(4):323\u201332.","DOI":"10.1056\/NEJMoa2509688"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10478-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10478-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10478-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:37:39Z","timestamp":1785350259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10478-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10478"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10478-4","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Human Ethics and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AT received honoraria for lectures from Stago and Werfen; VLM received consulting fees, travel support, or honoraria for lectures from Alfasigma, Bayer, Biomarin, CSL Behring, Gore, Sanofi, Takeda, and participated on advisory boards for Biomarin and Pfizer; FP received consulting fees, travel support, or honoraria for lectures from Astra Zeneca, Bracco, ESAOTE, EISAI, GE, Gilead, IPSEN, MSD, Nerviano NMS, Roche, Samsung, Siemens Healthineers, Signant Health, participated on advisory boards for Astra Zeneca, BMS, EISAI, MSD, Nerviano, Novo Nordisk, Roche, Siemens Healthineers; BS has no conflicts of interest to disclose; NR received honoraria from Stago; WA participated on advisory boards for Astra Zeneca, Bayer, Norgine, Regeneron.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}